Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515117 | 0.77 | NOS3 (0.41) | NOS3NOS2NOS1RAB9AIDO1 | |
| SCHEMBL9004361 | 0.76 | PDPK1 (0.37) | NOS3NOS2CYP2D6MEN1RECQL | |
| SCHEMBL6802213 | 0.74 | CYP2D6 (0.38) | NOS3NOS2CYP2D6MEN1RECQL | |
| SCHEMBL4589465 | 0.74 | CYP2D6 (0.38) | NOS3NOS2CYP2D6MEN1RECQL | |
| SCHEMBL3373290 | 0.74 | CYP2D6 (0.46) | NOS3NOS2CYP2D6MEN1RECQL | |
| SCHEMBL10514957 | 0.74 | MEN1 (0.35) | NOS3NOS2CYP2D6MEN1RECQL | |
| SCHEMBL8116855 | 0.71 | NOTUM (0.38) | NOS3NOS2CYP2D6MEN1RECQL | |
| SCHEMBL1849007 | 0.71 | CA1 (0.34) | NOS3NOS2CYP2D6MEN1RECQL | |
| SCHEMBL30358244 | 0.71 | TRPA1 (0.38) | NOS3NOS2CYP2D6MEN1RECQL | |
| SCHEMBL13620740 | 0.71 | TRPA1 (0.38) | NOS3NOS2CYP2D6MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| EP-3927705-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1st Biotherapeutics, Inc. (KR) | 2021-12-29 | — | — | EP | claimed |
| EP-3927706-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF PROLIFERATIVE DISORDERS | 1st Biotherapeutics, Inc. (KR) | 2021-12-29 | — | — | EP | claimed |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2021-11-11 | — | — | US | claimed |
| CN-113454082-A | Imidazopyridinyl compounds and their use for the treatment of neurodegenerative diseases | 第一生物治疗股份有限公司 | 2021-09-28 | — | — | CN | claimed |
| CN-113454081-A | Imidazopyridinyl compounds and their use for the treatment of proliferative diseases | 第一生物治疗股份有限公司 | 2021-09-28 | — | — | CN | claimed |
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2020-08-27 | — | — | US | claimed |
| EP-3692023-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1st Biotherapeutics, Inc. (KR) | 2020-08-12 | — | — | EP | claimed |
| WO-2019070093-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2019-04-11 | — | — | WO | claimed |
| US-20190100500-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2019-04-04 | — | — | US | claimed |
| EP-0712850-B1 | Herbicidal novel 1-cyclopropyl tetrazolinones | BAYER AGROCHEM KK (JP) | 2000-04-05 | — | — | EP | claimed |
| US-5668087-A | Herbicidal 1-alkenyltetrazolinones | NIHON BAYER AGROCHEM K.K. (JP) | 1997-09-16 | — | — | US | claimed |
| US-5654257-A | HERBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 1997-08-05 | — | — | US | claimed |
| EP-0733624-A1 | Herbicidal 1-alkenyltetrazolinones | NIHON BAYER AGROCHEM K.K. (JP) | 1996-09-25 | — | — | EP | claimed |
| EP-0728750-A1 | 1-Cycloalkenyltetrazolinones | NIHON BAYER AGROCHEM K.K. (JP) | 1996-08-28 | — | — | EP | claimed |
| EP-0431856-B1 | Heterocyclic compounds | ZENECA LTD (GB) | 1995-07-12 | — | — | EP | claimed |
| US-5332737-A | Cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-07-26 | — | — | US | claimed |
| US-5128227-A | Electrography, improved chargability | AGFA-GEVAERT, N.V. (BE) | 1992-07-07 | — | — | US | claimed |
| EP-0448843-A1 | Electrophotographic recording material | AGFA-GEVAERT N.V. (BE) | 1991-10-02 | — | — | EP | claimed |
| EP-0431856-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1991-06-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100500-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | ABL2, ABL1, MAPT | NOS3 2934/4885NOS2 2662/4885CYP2D6 4738/4885 |
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | NOS3 2538/4885NOS2 3007/4885CYP2D6 2353/4885 |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | NOS3 2538/4885NOS2 3007/4885CYP2D6 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.